Status:
COMPLETED
Register Study of the Neoadjuvanten Treatment by Patients With Rectumcarcinoma
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Feasibilitystudy
Eligibility:
All Genders
18-80 years
Brief Summary
goal of this study is to check the effecivity, feasibility and toxicity of the chemoradiotherapy and hyperthermia
Detailed Description
Radiation: 5x1,8Gy until 50,4 Gy Hyperthermia: 2x/week Chemotherapy: neoadjuvant= day 1-5 and day 29-33 5FU 1000mg/m2 adjuvant = 4 Cycles 5FU 500mg/m2 all 4 weeks
Eligibility Criteria
Inclusion
- adenocarcinoma until 10 cm until ano UICC II+III 18-80 years old ECOG PS 0-2 Informed Consent
Exclusion
- cardiac insufficiency last 6 month heartattack nodal AV pressure III° hip prothesis cardiac pacemaker others contraindikations against the therapie radiation of pelvis chronic gestrointestinal desaese gestation or lactation previous radiotion pelvis previous Chemotherapie second carcinoma beside baslioma infiltation in analarea
Key Trial Info
Start Date :
August 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2017
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT03428867
Start Date
August 1 2012
End Date
July 31 2017
Last Update
February 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Tuebingen
Tübingen, Baden-Wurttemberg, Germany, 72070